tirzepatide cancer risk BREAKING NEWS 🚨 A new study from the University of Michigan found that SHRINKS BREAST TUMORS IN MICE. For women 40–55, this matters. Weight gain and breast cancer both New study links GLP-1 drugs

[1] [2] Key eligibility criteria include a BMI of 35 kg/m or above with at least one weight-related comorbidity, or a BMI of 3034.9 kg/m in specific circumstances

Mounjaro tends to win the Mounjaro vs Ozempic decision for patients who: Have obesity (BMI 30) or are overweight with metabolic risk factors, and weight loss is the primary goal Have an HbA1c that hasnt responded well to metformin or older GLP-1 drugs Dont have a strong personal or family history of cardiovascular disease that specifically needs Ozempics proven protective data Can sustain the higher monthly cost for the 12+ months typically needed for lasting results Who Should Consider Ozempic (or Generic Semaglutide)

A., Shahzad, M

See how many clicks equal your prescribed tirzepatide dose

Adriane Fugh-Berman, a physician and professor at Georgetown University, also challenged the idea that allowing legal versions would eliminate this gray market

Some patients report that these opposing effects partially cancel each other out, with phentermine providing energy during the day while tirzepatide reduces caloric intake throughout the full 24-hour cycle